本文選題：達(dá)格列凈 + 鈉-葡萄糖其轉(zhuǎn)運(yùn)蛋白抑制劑　； 參考：《沈陽(yáng)藥科大學(xué)學(xué)報(bào)》2017年10期

【摘要】：目的系統(tǒng)評(píng)價(jià)鈉-葡萄糖共轉(zhuǎn)運(yùn)蛋白2(sodium-dependent glucose transporter 2,SGLT-2)抑制劑達(dá)格列凈治療2型糖尿病(type 2 diabetes,T2DM)患者的有效性和安全性。方法計(jì)算機(jī)檢索Pub Med、The Cochrane Library、EMbase、中國(guó)知網(wǎng)和萬(wàn)方數(shù)據(jù)庫(kù),檢索時(shí)限截止至2016年3月,由兩名研究者分別對(duì)納入文獻(xiàn)進(jìn)行數(shù)據(jù)提取與質(zhì)量評(píng)價(jià)后,采用Rev Man 5.3和Stata12.0軟件進(jìn)行Meta分析。結(jié)果納入19個(gè)隨機(jī)對(duì)照試驗(yàn),共8 618例患者。Meta分析結(jié)果顯示,與安慰劑相比,達(dá)格列凈組患者糖化血紅蛋白(hemoglobin A1c,Hb A1c)水平降低[WMD=-0.49,95%CI(-0.65,-0.34),P0.001];體重減輕[(WMD=-1.84 kg,95%CI(-2.09,-1.59),P0.001];收縮壓[WMD=-3.07,95%CI(-3.92,-2.23),P0.001]和舒張壓[WMD=-1.66,95%CI(-2.30,-1.01),P0.001]均有所下降,總不良反應(yīng)發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義[RR=1.10,95%CI(0.99,1.22),P=0.09];低血糖發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義[RR=1.10,95%CI(0.99,1.24),P=0.09];泌尿系感染發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義[RR=1.09,95%CI(0.92,1.29),P=0.34];腎功能損傷發(fā)生率[RR=1.78,95%CI(1.04,3.05),P=0.03]以及生殖系感染發(fā)生率[RR=3.27,95%CI(2.39,4.47),P0.001]均增高。結(jié)論達(dá)格列凈雖增加生殖系感染發(fā)生率及腎功能損傷發(fā)生率,但能有效降低T2DM患者Hb A1c水平、體重和血壓,影響血脂水平,不良反應(yīng)發(fā)生率、低血糖發(fā)生率和泌尿系感染的發(fā)生率與安慰劑相當(dāng)。
[Abstract]:Objective to evaluate the efficacy and safety of sodium glucose cotransporter (2(sodium-dependent glucose transporter 2) SGLT-2 inhibitor Daglitrine in the treatment of type 2 diabetes mellitus (T2DM). Methods the Cochrane Library EMbase, China knowledge Network and Wanfang database were searched by computer. The retrieval time was up to March 2016. After data extraction and quality evaluation were carried out by two researchers respectively, Meta-analysis was carried out by Rev Man 5.3 and Stata12.0 software. 緇撴灉綰沖叆19涓殢鏈哄鐓ц瘯楠，

本文編號(hào)：1981703